Tocilizumab, an interleukin-6 receptor inhibitor marketed as Actemra, significantly increased the height velocities of most patients with systemic juvenile idiopathic arthritis, according to a study presented at the American College of Rheumatology meeting. Higher insulinlike growth factor-1 levels and osteocalcin/C-telopeptide of type 1 collagen ratios linked to the use of the drug suggests the treatment can benefit growth hormone axis and bone metabolism, researchers said.
Tocilizumab can boost catch-up growth in systemic JIA
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||